460 related articles for article (PubMed ID: 25561537)
1. Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis.
Tyagi S; Ammerman NC; Li SY; Adamson J; Converse PJ; Swanson RV; Almeida DV; Grosset JH
Proc Natl Acad Sci U S A; 2015 Jan; 112(3):869-74. PubMed ID: 25561537
[TBL] [Abstract][Full Text] [Related]
2. Clofazimine Contributes Sustained Antimicrobial Activity after Treatment Cessation in a Mouse Model of Tuberculosis Chemotherapy.
Swanson RV; Ammerman NC; Ngcobo B; Adamson J; Moodley C; Dorasamy A; Moodley S; Mgaga Z; Bester LA; Singh SD; Almeida DV; Grosset JH
Antimicrob Agents Chemother; 2016 May; 60(5):2864-9. PubMed ID: 26926638
[TBL] [Abstract][Full Text] [Related]
3. Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs.
Clemens DL; Lee BY; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ding X; Ho CM; Horwitz MA
PLoS One; 2019; 14(5):e0215607. PubMed ID: 31075149
[TBL] [Abstract][Full Text] [Related]
4. Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice.
Grosset JH; Tyagi S; Almeida DV; Converse PJ; Li SY; Ammerman NC; Bishai WR; Enarson D; Trébucq A
Am J Respir Crit Care Med; 2013 Sep; 188(5):608-12. PubMed ID: 23822735
[TBL] [Abstract][Full Text] [Related]
5. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.
Rosenthal IM; Zhang M; Williams KN; Peloquin CA; Tyagi S; Vernon AA; Bishai WR; Chaisson RE; Grosset JH; Nuermberger EL
PLoS Med; 2007 Dec; 4(12):e344. PubMed ID: 18092886
[TBL] [Abstract][Full Text] [Related]
6. Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis.
Ding Y; Zhu H; Fu L; Zhang W; Wang B; Guo S; Chen X; Wang N; Liu H; Lu Y
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0065822. PubMed ID: 35924925
[TBL] [Abstract][Full Text] [Related]
7. Treatment-Shortening Effect of a Novel Regimen Combining Clofazimine and High-Dose Rifapentine in Pathologically Distinct Mouse Models of Tuberculosis.
Saini V; Ammerman NC; Chang YS; Tasneen R; Chaisson RE; Jain S; Nuermberger E; Grosset JH
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30936097
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the efficacy of clofazimine alone and in combination with primary agents against Mycobacterium tuberculosis in vitro.
Mashele SA; Steel HC; Matjokotja MT; Rasehlo SSM; Anderson R; Cholo MC
J Glob Antimicrob Resist; 2022 Jun; 29():343-352. PubMed ID: 35339735
[TBL] [Abstract][Full Text] [Related]
9. Impact of Clofazimine Dosing on Treatment Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis.
Ammerman NC; Swanson RV; Bautista EM; Almeida DV; Saini V; Omansen TF; Guo H; Chang YS; Li SY; Tapley A; Tasneen R; Tyagi S; Betoudji F; Moodley C; Ngcobo B; Pillay L; Bester LA; Singh SD; Chaisson RE; Nuermberger E; Grosset JH
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29735562
[TBL] [Abstract][Full Text] [Related]
10. Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis.
Ibrahim M; Truffot-Pernot C; Andries K; Jarlier V; Veziris N
Am J Respir Crit Care Med; 2009 Sep; 180(6):553-7. PubMed ID: 19590024
[TBL] [Abstract][Full Text] [Related]
11. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
Wada M
Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
[TBL] [Abstract][Full Text] [Related]
12. Sterilizing Activity of Pyrazinamide in Combination with First-Line Drugs in a C3HeB/FeJ Mouse Model of Tuberculosis.
Lanoix JP; Betoudji F; Nuermberger E
Antimicrob Agents Chemother; 2016 Feb; 60(2):1091-6. PubMed ID: 26643352
[TBL] [Abstract][Full Text] [Related]
13. Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.
Williams K; Minkowski A; Amoabeng O; Peloquin CA; Taylor D; Andries K; Wallis RS; Mdluli KE; Nuermberger EL
Antimicrob Agents Chemother; 2012 Jun; 56(6):3114-20. PubMed ID: 22470112
[TBL] [Abstract][Full Text] [Related]
14. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
15. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society.
Monaldi Arch Chest Dis; 1994 Sep; 49(4):327-45. PubMed ID: 8000420
[TBL] [Abstract][Full Text] [Related]
16. Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis.
Williams KN; Brickner SJ; Stover CK; Zhu T; Ogden A; Tasneen R; Tyagi S; Grosset JH; Nuermberger EL
Am J Respir Crit Care Med; 2009 Aug; 180(4):371-6. PubMed ID: 19520903
[TBL] [Abstract][Full Text] [Related]
17. TB47 and clofazimine form a highly synergistic sterilizing block in a second-line regimen for tuberculosis in mice.
Yu W; Chiwala G; Gao Y; Liu Z; Sapkota S; Lu Z; Guo L; Khan SA; Zhong N; Zhang T
Biomed Pharmacother; 2020 Nov; 131():110782. PubMed ID: 33152940
[TBL] [Abstract][Full Text] [Related]
18. Clofazimine has delayed antimicrobial activity against Mycobacterium tuberculosis both in vitro and in vivo.
Ammerman NC; Swanson RV; Tapley A; Moodley C; Ngcobo B; Adamson J; Dorasamy A; Moodley S; Mgaga Z; Bester LA; Singh SD; Almeida DV; Grosset JH
J Antimicrob Chemother; 2017 Feb; 72(2):455-461. PubMed ID: 27798204
[TBL] [Abstract][Full Text] [Related]
19. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
Rosenthal IM; Williams K; Tyagi S; Peloquin CA; Vernon AA; Bishai WR; Grosset JH; Nuermberger EL
Am J Respir Crit Care Med; 2006 Jul; 174(1):94-101. PubMed ID: 16574936
[TBL] [Abstract][Full Text] [Related]
20. Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis.
Veziris N; Ibrahim M; Lounis N; Andries K; Jarlier V
PLoS One; 2011 Mar; 6(3):e17556. PubMed ID: 21408613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
